Article Information
History
- August 7, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- C Serre-Miranda1,2,#,
- C Nobrega1,2,#,
- S Roque1,2,#,
- J Canto-Gomes1,2,
- CS Silva1,2,
- N Vieira1,2,
- P Barreira-Silva1,2,
- P Alves-Peixoto1,2,
- J Cotter1,2,3,
- A Reis3,
- M Formigo3,
- H Sarmento3,
- O Pires4,
- A Carvalho1,2,4,
- DY Petrovykh5,
- L Diéguez5,
- JC Sousa1,2,
- N Sousa1,2,6,
- C Capela1,2,4,
- JA Palha1,2,6,
- PG Cunha1,2,3 and
- M Correia-Neves1,2,6,*
- 1Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- 2ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
- 3Center for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Internal Medicine Department, Senhora da Oliveira Hospital, Guimarães, Portugal
- 4Hospital of Braga, Braga, Portugal
- 5International Iberian Nanotechnology Laboratory (INL), Braga, Portugal
- 6Clinical Academic Center, Braga, Portugal
- ↵*Corresponding author:
Margarida Correia-Neves, Life and Health Sciences Research Institute, School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal. E-mail: mcorreianeves{at}med.uminho.pt; Phone: +351 253 604 807.
↵# Authors contributed equally
Posted August 07, 2020.
Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients
